.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,518,298

« Back to Dashboard

Details for Patent: 6,518,298

Title: Methods and compositions for inhibition of angiogenesis with EM-138
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
Inventor(s): Green; Shawn J. (Vienna, VA), Swartz, Jr.; Glenn M. (Jessup, MD), Shah; Jamshed H. (Columbia, MD), Madsen; John (Knoxville, MD), D'Amato; Robert J. (Cambridge, MA)
Assignee: Entremed, Inc. (Rockville, MD)
Filing Date:Feb 20, 2001
Application Number:09/788,872
Claims:1. A method of treating a non-tumor blood condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138 ##STR25##

2. The method of claim 1 wherein the undesired angiogenesis occurs in polyarteritis.

3. The method of claim 1 wherein the undesired angiogenesis occurs in sickle cell anemia.

4. The method of claim 1 wherein the undesired angiogenesis occurs in vein occlusion.

5. The method of claim 1 wherein the undesired angiogenesis occurs in artery occlusion.

6. The method of claim 1 wherein the undesired angiogenesis occurs in carotid obstructive disease.

7. The method of claim 1 wherein the undesired angiogenesis occurs in atherosclerosis.

8. The method of claim 1 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

9. The method of claim 8 wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

10. The method of claim 9 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

11. The method of claim 1 wherein the compound is administered in the form of a tablet.

12. The method of claim 1 wherein the compound is administered in the form of a capsule.

13. The method of claim 1 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

14. The method of claim 1 wherein the administration is oral.

15. The method of claim 1 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

16. The method of claim 1 wherein the administration is parenteral.

17. The method of claim 1 wherein the administration is transdermal or topical.

18. The method of claim 1 wherein the undesired angiogenesis occurs in Osler-Weber-Rendu disease.

19. A method of treating an immune disease associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138 ##STR26##

20. The method of claim 19 wherein the undesired angiogenesis occurs in rheumatoid arthritis.

21. The method of claim 19 wherein the undesired angiogenesis occurs in systemic lupus.

22. The method of claim 19 wherein the undesired angiogenesis occurs in osteoarthritis.

23. The method of claim 19 wherein the undesired angiogenesis occurs in acquired immune deficiency syndrome.

24. The method of claim 19 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

25. The method of claim 24 wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

26. The method of claim 25 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

27. The method of claim 19 wherein the compound is administered in the form of a tablet.

28. The method of claim 19 wherein the compound is administered in the form of a capsule.

29. The method of claim 19 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

30. The method of claim 19 wherein the administration is oral.

31. The method of claim 19 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

32. The method of claim 19 wherein the administration is oral, parenteral, transdermal or topical.

33. The method treating an infection associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138 ##STR27##

34. The method of claim 33 wherein the undesired angiogenesis occurs in sysphilis.

35. The method of claim 33 wherein the undesired angiogenesis occurs in Mycobacteria infections.

36. The method of claim 33 wherein the undesired angiogenesis occurs in Herpes simplex infections.

37. The method of claim 33 wherein the undesired angiogenesis occurs in Herpes zoster infections.

38. The method of claim 33 wherein the undesired angiogenesis occurs in protazoan infections.

39. The method of claim 33 wherein the undesired angiogenesis occurs in toxoplasmosis.

40. The method of claim 33 wherein the undesired angiogenesis occurs in Bartonellosis.

41. The method of claim 33 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

42. The method of claim 41 wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

43. The method of claim 42 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

44. The method of claim 33 wherein the compound is administered in the form of a tablet.

45. The method of claim 33 wherein the compound is administered in the form of a capsule.

46. The method of claim 33 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

47. The method of claim 33 wherein the administration is oral.

48. The method of claim 33 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

49. The method of claim 33 wherein the administration is oral, parenteral, transdermal or topical.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc